Literature DB >> 18594469

Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity.

Stefano Gobbo1, John N Eble, David J Grignon, Guido Martignoni, Gregory T MacLennan, Rajal B Shah, Shaobo Zhang, Matteo Brunelli, Liang Cheng.   

Abstract

A group of renal tumors composed mainly of cells with clear cytoplasm arranged in papillary patterns and arising in end-stage kidneys has recently been identified. The aim of our study is to investigate the cytogenetic and immunohistochemical phenotypes of these unusual renal tumors, and of morphologically similar tumors arising in kidneys unaffected by end-stage renal disease. Seven tumors from 5 patients (age range: 53 to 64 y, mean: 60 y; 3 men and 2 women) were identified. Sections were obtained from paraffin blocks, including the tumors and adjacent non-neoplastic renal parenchyma. Interphase fluorescence in situ hybridization was performed with centromeric probes for chromosomes 3, 7, 17, Y, and with a subtelomeric probe for 3p25. Immunohistochemistry was performed with antibodies against cytokeratin 7, carbonic anhydrase IX, alpha-methylacyl-CoA racemase, CD10, and transcription factor E3. Four of the tumors were from patients who did not have end-stage renal disease. One patient had end-stage renal disease and presented with 3 morphologically identical tumors, composed of clear cells arranged in a mixture of cystic and papillary structures. Follow-up data were available from all patients and none showed recurrence or metastasis (mean follow-up: 24 mo). All 7 tumors (ranging from 4 to 50 mm in diameter) were stage pT1. All tumors lacked the gains of chromosome 7 and losses of chromosome Y that are typical of papillary renal cell carcinoma. Only 1 tumor showed gain of chromosome 17. Deletion of 3p, usually seen in clear cell renal cell carcinoma, was not detected. All tumors showed strongly positive immunohistochemical staining for cytokeratin 7 and carbonic anhydrase IX and negative immunostaining with antibodies against alpha-methylacyl-CoA racemase, CD10, and transcription factor E3. In conclusion, clear cell papillary renal cell carcinoma can arise in otherwise normal kidneys and in kidneys with end-stage renal disease. This tumor has immunophenotypic and genetic profiles distinct from those of either classic papillary or clear cell renal cell carcinoma, and should be considered a distinct entity in the spectrum of renal cell neoplasia.

Entities:  

Mesh:

Year:  2008        PMID: 18594469     DOI: 10.1097/PAS.0b013e318164bcbb

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  56 in total

1.  [Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)].

Authors:  G Kristiansen; B Delahunt; J R Srigley; C Lüders; J-M Lunkenheimer; H Gevensleben; T Thiesler; R Montironi; L Egevad
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

2.  Genomic profiling of renal cell carcinoma in patients with end-stage renal disease.

Authors:  Toru Inoue; Keiko Matsuura; Taichiro Yoshimoto; Lam Tung Nguyen; Yoshiyuki Tsukamoto; Chisato Nakada; Naoki Hijiya; Takahiro Narimatsu; Takeo Nomura; Fuminori Sato; Yoji Nagashima; Kenji Kashima; Shingo Hatakeyama; Chikara Ohyama; Kazuyuki Numakura; Tomonori Habuchi; Masayuki Nakagawa; Masao Seto; Hiromitsu Mimata; Masatsugu Moriyama
Journal:  Cancer Sci       Date:  2012-01-20       Impact factor: 6.716

3.  An analysis of five clear cell papillary cystadenomas of mesosalpinx and broad ligament: four associated with von Hippel-Lindau disease and one aggressive sporadic type.

Authors:  Francisco F Nogales; Pablo Goyenaga; Ovidiu Preda; Alina Nicolae; Begoña Vieites; Maria Carmen Ruiz-Marcellan; Alberto Pedrosa; Maria J Merino
Journal:  Histopathology       Date:  2012-02-01       Impact factor: 5.087

4.  Urothelial carcinoma of the renal pelvis with simultaneous trophoblastic and malignant clear cell endodermal-type differentiation.

Authors:  Ovidiu Preda; Alis Dema; Mihaela Iacob; Pablo Goyenaga; Isabel Dulcey; José Aneiros Fernández; Francisco F Nogales
Journal:  Virchows Arch       Date:  2012-02-24       Impact factor: 4.064

Review 5.  Chinese guidelines on the management of renal cell carcinoma (2015 edition).

Authors:  Jun Guo; Jianhui Ma; Yan Sun; Shukui Qin; Dingwei Ye; Fangjian Zhou; Zhisong He; Xinan Sheng; Feng Bi; Dengfeng Cao; Yingxia Chen; Yiran Huang; Houjie Liang; Jun Liang; Jiwei Liu; Wenchao Liu; Yueyin Pan; Yongqian Shu; Xin Song; Weibo Wang; Xiuwen Wang; Xiaoan Wu; Xiaodong Xie; Xin Yao; Shiying Yu; Yanqiao Zhang; Aiping Zhou
Journal:  Ann Transl Med       Date:  2015-11

6.  Renal tumors: diagnostic and prognostic biomarkers.

Authors:  Puay Hoon Tan; Liang Cheng; Nathalie Rioux-Leclercq; Maria J Merino; George Netto; Victor E Reuter; Steven S Shen; David J Grignon; Rodolfo Montironi; Lars Egevad; John R Srigley; Brett Delahunt; Holger Moch
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

7.  Renal angiomyoadenomatous tumor: morphologic, immunohistochemical, and molecular genetic study of a distinct entity.

Authors:  J Verine
Journal:  Virchows Arch       Date:  2009-02-10       Impact factor: 4.064

8.  Clear cell papillary renal cell carcinoma with angiomyomatous stroma: a histological, immunohistochemical, and fluorescence in situ hybridization study.

Authors:  Borislav A Alexiev; Carrie Thomas; Ying S Zou
Journal:  Virchows Arch       Date:  2014-04-27       Impact factor: 4.064

9.  Coexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): implications for a possible role of SWI/SNF complex in the pathogenesis of RCC.

Authors:  Qiu Rao; Qiu-Yuan Xia; Qin Shen; Shan-Shan Shi; Pin Tu; Qun-Li Shi; Xiao-Jun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

10.  Sporadic hemangioblastoma of the kidney with PAX2 and focal CD10 expression: report of a case.

Authors:  Jin-Gui Jiang; Qiu Rao; Qiu-Yuan Xia; Pin Tu; Zhen-Feng Lu; Qin Shen; Ru-Song Zhang; Bo Yu; Xiao-Jun Zhou; Shan-Shan Shi; Qun-Li Shi
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.